share_log

Afya Analyst Ratings

Afya Analyst Ratings

Afya 分析師評級
Benzinga ·  2023/10/13 05:49
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/13/2023 32.86% Morgan Stanley $16.5 → $20.5 Upgrades Equal-Weight → Overweight
11/22/2022 16.66% Credit Suisse $19 → $18 Maintains Outperform
04/08/2022 23.14% Credit Suisse $18 → $19 Upgrades Neutral → Outperform
03/07/2022 36.1% UBS $27 → $21 Maintains Buy
07/21/2021 84.71% Morgan Stanley $32 → $28.5 Downgrades Overweight → Equal-Weight
04/15/2021 UBS Upgrades Neutral → Buy
02/04/2021 120.35% JP Morgan → $34 Upgrades Neutral → Overweight
10/19/2020 107.39% JP Morgan → $32 Downgrades Overweight → Neutral
09/28/2020 95.72% Goldman Sachs → $30.2 Upgrades Neutral → Buy
09/15/2020 107.39% B of A Securities → $32 Reinstates → Buy
08/19/2020 68.5% Credit Suisse → $26 Initiates Coverage On → Neutral
05/20/2020 39.34% UBS → $21.5 Downgrades Buy → Neutral
05/05/2020 58.78% JP Morgan $33 → $24.5 Maintains Overweight
03/09/2020 113.87% JP Morgan $35 → $33 Maintains Overweight
01/15/2020 100.91% UBS $29 → $31 Maintains Buy
09/19/2019 87.95% UBS → $29 Initiates Coverage On → Buy
08/13/2019 87.95% B of A Securities → $29 Initiates Coverage On → Buy
08/13/2019 68.5% Goldman Sachs → $26 Initiates Coverage On → Neutral
08/13/2019 89.24% Morgan Stanley → $29.2 Initiates Coverage On → Overweight
08/09/2019 120.35% JP Morgan → $34 Initiates Coverage On → Overweight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年10月13日 32.86% 摩根士丹利 $16.5→$20.5 升級 等重→超重
2022年11月22日 16.66% 瑞士信貸 $19→$18 維護 跑贏大盤
04/08/2022 23.14% 瑞士信貸 $18→$19 升級 中性→表現優異
03/07/2022 36.1% 瑞銀集團 $27→$21 維護
07/21/2021 84.71% 摩根士丹利 $32→$28.5 評級下調 超重→等重
04/15/2021 - 瑞銀集團 升級 中性→購買
02/04/2021 120.35% 摩根大通 →$34 升級 中性→超重
10/19/2020 107.39% 摩根大通 →$32 評級下調 超重→中性
09/28/2020 95.72% 高盛 →$30.2 升級 中性→購買
2020/09/15 107.39% B of A證券 →$32 恢復 →購買
2020年08月19日 68.5% 瑞士信貸 →$26 開始承保 →中性
05/20/2020 39.34% 瑞銀集團 →$21.5 評級下調 購買→中性
05/05/2020 58.78% 摩根大通 $33→$24.5 維護 超重
03/09/2020 113.87% 摩根大通 $35→$33 維護 超重
2020/01/15 100.91% 瑞銀集團 $29→$31 維護
2019年09月19日 87.95% 瑞銀集團 →$29 開始承保 →購買
2019年08月13日 87.95% B of A證券 →$29 開始承保 →購買
2019年08月13日 68.5% 高盛 →$26 開始承保 →中性
2019年08月13日 89.24% 摩根士丹利 →$29.2 開始承保 →超重
2019年08月09日 120.35% 摩根大通 →$34 開始承保 →超重

What is the target price for Afya (AFYA)?

阿夫亞(Afya)的目標價是多少?

The latest price target for Afya (NASDAQ: AFYA) was reported by Morgan Stanley on October 13, 2023. The analyst firm set a price target for $20.50 expecting AFYA to rise to within 12 months (a possible 32.86% upside). 2 analyst firms have reported ratings in the last year.

阿夫亞(納斯達克:AFYA)的最新目標價是摩根士丹利在2023年10月13日報道的。這家分析公司將目標價定為20.50美元,預計Afya將在12個月內上漲(可能上漲32.86%)。去年有兩家分析公司公佈了評級。

What is the most recent analyst rating for Afya (AFYA)?

分析師對Afya(Afya)的最新評級是多少?

The latest analyst rating for Afya (NASDAQ: AFYA) was provided by Morgan Stanley, and Afya upgraded their overweight rating.

納斯達克:AFYA最新分析師評級由摩根士丹利提供,AFYA上調增持評級。

When is the next analyst rating going to be posted or updated for Afya (AFYA)?

下一次發佈或更新Afya(Afya)分析師評級的時間是什麼時候?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Afya, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Afya was filed on October 13, 2023 so you should expect the next rating to be made available sometime around October 13, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與Afya的高管和客戶交談,以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Afya的上一次評級是在2023年10月13日提交的,所以你應該預計下一次評級將在2024年10月13日左右提供。

Is the Analyst Rating Afya (AFYA) correct?

分析師對Afya(Afya)的評級正確嗎?

While ratings are subjective and will change, the latest Afya (AFYA) rating was a upgraded with a price target of $16.50 to $20.50. The current price Afya (AFYA) is trading at is $15.43, which is out of the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的Afya(Afya)評級被上調,目標價為16.50美元至20.50美元。Afya(Afya)目前的交易價格為15.43美元,超出了分析師的預測區間。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論